This study involved POAG patients who were enrolled in the Investigating Glaucoma Progression Study, which is an ongoing prospective study of glaucoma patients at the Glaucoma Clinic of Seoul National University Bundang Hospital. All subjects provided written informed consent to participate. The study protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital and followed the tenets of the Declaration of Helsinki.
All participants underwent comprehensive ophthalmic examinations, which included assessments of the best-corrected visual acuity (BCVA), Goldmann applanation tonometry, a refraction test, slit-lamp biomicroscopy, gonioscopy, stereo disc photography, red-free fundus photography (EOS D60 digital camera; Canon, Utsunomiyashi, Japan), central corneal thickness measurement (Orbscan II; Bausch & Lomb Surgical, Rochester, NY, USA), axial length measurement (IOLMaster version 5; Carl Zeiss Meditec, Dublin, CA, USA), and corneal curvature measurement (KR-1800; Topcon, Tokyo, Japan). The peripapillary RNFL thickness was measured by spectral-domain OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany). Other ophthalmic examinations included standard automated perimetry (Humphrey Field Analyzer II 750, 24–2 Swedish interactive threshold algorithm; Carl Zeiss Meditec), enhanced depth-imaging (EDI) spectral-domain OCT scanning of the optic nerve head (ONH) (Spectralis; Heidelberg Engineering), and swept-source OCTA (DRI OCT Triton; Topcon).
The clinical history of the participants was also obtained, including demographic characteristics and the presence of cold extremities, migraine, and other systemic conditions. Systolic and diastolic blood pressures (BPs) were measured using a digital automatic BP monitor (Omron HEM-770A; Omron Matsusaka, Matsusaka, Japan). The mean arterial pressure (MAP) was calculated as diastolic BP + 1/3(systolic BP − diastolic BP), and the mean ocular perfusion pressure was calculated as 2/3(MAP − IOP) at the time of OCTA.
POAG was defined as the presence of an open iridocorneal angle, signs of glaucomatous optic nerve damage (i.e., neuroretinal rim thinning, notching, or an RNFL defect), and a glaucomatous visual field (VF) defect. A glaucomatous VF defect was defined as one conforming with one or more of the following criteria: (1) outside normal limits on a glaucoma hemifield test, (2) three abnormal points with a <5% probability of being normal and one abnormal point with a <1% probability by pattern deviation, or (3) a pattern standard deviation of probability <5% confirmed on two consecutive reliable tests (fixation loss rate of ≤20% and false-positive error rate of ≤15% and false-negative error rate of ≤25%).
For eyes to be included, a record was required of the untreated IOP being measured before the initiation of ocular hypotensive treatment or as identified in the referral notes. In patients with an untreated IOP ≤21 mm Hg, the diurnal variation was measured during office hours (every 2 hours from 9 AM to 5 PM), and the mean of the five values was considered an untreated IOP. In patients with an untreated IOP >21 mm Hg, IOP was measured twice before starting IOP-lowering medication, and the mean of the two values was considered the untreated IOP. In patients who were undergoing treatment with ocular hypotensive medication at the time of the initial visit, the diurnal variation was measured after a 4-week washout period. Eyes were also required to have been followed for at least 2.5 years, during which the RNFL thickness was measured by serial spectral-domain OCT at least five times.
The exclusion criteria were eyes with a BCVA worse than 20/40, a spherical equivalent of <–9.0 diopters (D) or >+3.0 D, a cylinder correction of <–3.0 D or >+3.0 D, a history of intraocular surgery with the exception of uneventful cataract surgery, and retinal diseases (e.g., diabetic retinopathy, retinal vessel occlusion, or retinoschisis) or neurological diseases (e.g., pituitary tumor).